Takenori Niioka

Takenori Niioka

Auto-generated profile, based on publicly available information

Takenori Niioka

Department of Pharmacy, Akita University Hospital; †Division of Blood Transfusion, Akita University Hospital; and ‡Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2020 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
JNJunichi Nakagawa
Junichi Nakagawa
TKTakahiko Kinjo
Takahiko Kinjo
MIMei Iizuka
Mei Iizuka
KUKayo Ueno
Kayo Ueno
HTHirofumi Tomita
Hirofumi Tomita
TNTakenori Niioka
Takenori Niioka

1 October 2017 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
TNTakenori Niioka
Takenori Niioka
NFNaohito Fujishima
Naohito Fujishima
MAMaiko Abumiya
Maiko Abumiya
TYTakaya Yamashita
Takaya Yamashita
KUKumi Ubukawa
Kumi Ubukawa
MMMasatomo Miura
Masatomo Miura
Background: Although voriconazole (VRCZ) is metabolized to VRCZN-oxide principally by CYP2C19, VRCZ clearance is affected by multiple factors. In this study, we investigated the relationship between the CYP2C19 phenotype using the VRCZ-to-VRCZN-oxide plasma concentration ratio (VRCZ/N-oxide) and demographic and clinical characteristics of Japanese patients taking VRCZ.Methods: A total of 65 Japanese patients taking VRCZ for prophylaxis or treatment of fungal infection were enrolled in this study. Stepwise selection multiple linear regression analysis was performed to investigate the effect of factors on the VRCZ/N-oxide ratio.Results: In patients not undergoing concurrent treatment with a drug influencing CYP2C19 activity (n = 54), the VRCZ/N-oxide ratio with definite thresholds for CYP2C19 genotypes,CYP2C19*1/*1,*1/*2+*1/*3+*2/*17, and*2/*2+*2/*3, was specifically identified in patients taking VRCZ (<0.48, ≥0.48 < and <0.82 and ≥0.82). However, the VRCZ/N-oxide ratio could not be predicted based solely on the CYP2C19 genotype (R2= 0.053). The route of VRCZ administration, C-reactive protein concentration determined on the same day as VRCZ plasma concentration measurement, CYP2C19 extensive metabolizer, and patient age were independent factors influencing the VRCZ/N-oxide ratio (R2= 0.489, standardized regression coefficient = 0.385, 0.380, −0.231, and 0.231;P= 0.001, 0.001, 0.032, and 0.036, respectively).Conclusions: It is possible to comprehensively evaluate CYP2C19 activity using the actual measured value of the VRCZ/N-oxide ratio in patients taking VRCZ. The predictive performance of the VRCZ/N-oxide ratio was improved by including the route of administration, C-reactive protein level, and patient age in addition to the CYP2C19 genotype as predictive factors.

23 February 2022 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
NANaoya Aiuchi
Naoya Aiuchi
JNJunichi Nakagawa
Junichi Nakagawa
HSHirotake Sakuraba
Hirotake Sakuraba
TTTakenori Takahata
Takenori Takahata
KKKosuke Kamata
Kosuke Kamata
TNTakenori Niioka
Takenori Niioka
The effects of inflammatory responses and polymorphisms of the genes encoding cytochrome P450 (CYP) (CYP2C19 and CYP3A5), flavin‐containing monooxygenase 3 (FMO3), pregnane X receptor (NR1I2), constitutive androstane receptor (NR1I3), and CYP oxidoreductase (POR) on the ratio of voriconazole (VRCZ) N‐oxide to VRCZ (VNO/VRCZ) and steady‐state trough concentrations (C0h) of VRCZ were investigated. A total of 56 blood samples were collected from 36 Japanese patients. Results of multiple linear regression analyses demonstrated that the presence of the extensive metabolizer CYP2C19 genotype, the dose per administration, and the presence of the NR1I2 rs3814057 C/C genotype were independent factors influencing the VNO/VRCZ ratio in patients with CRP levels of less than 40 mg/L (standardized regression coefficients (SRC) = 0.448, −0.301, and 0.390, respectively; all p < .05). With regard to the concentration of VRCZ itself, in addition to the above factors, the presence of the NR1I2 rs7643645 G/G and rs3814055 T/T genotypes were found to be independent factors influencing the VRCZ C0h in these patients (SRC = −0.430, 0.424, −0.326, 0.406 and −0.455, respectively; all p < .05). On the contrary, in patients with CRP levels of at least 40 mg/L, no independent factors were found to affect VNO/VRCZ and VRCZ C0h. Inflammatory responses, and CYP2C19 and NR1I2 polymorphisms may be useful information for the individualization of VRCZ dosages.

1 April 2013 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
TNTakenori Niioka
Takenori Niioka
MMMasatomo Miura
Masatomo Miura
HKHideaki Kagaya
Hideaki Kagaya
MSMitsuru Saito
Mitsuru Saito
KNKazuyuki Numakura
Kazuyuki Numakura
SSShigeru Satoh
Shigeru Satoh
The aim of this study was to develop a limited sampling strategy to estimate the area under the concentration-time curve (AUC) of a modified-release, once-daily formulation of tacrolimus (Advagraf, Japanese trade name Graceptor) with Japanese renal transplant patients. Among the 43 enrolled patients, 23 patients continued to take Graceptor for 1 year. A total of 66 profiles on day 28 and day 365 from the 43 patients were randomly divided into a training group (N = 33) and a validation group (N = 33) without any overlap. The prediction formula for the AUC 0-24 using the single C 12h time point gave the highest correlation with the observed AUC 0-24 (r2 = 0.9057). When 2 sampling times were used, C 0h-C 12h were the best time points for the estimation of the AUC 0-24 (AUC 0-24 = 26.8 + 8.0C 0h + 17.8C 12h, r2 = 0.9221, P < 0.0001). There was no significant difference in the prediction error for the prediction formulas with the C 0h-C 12h combination between CYP3A5 genotypes. The % mean prediction error, % mean absolute error, and % root mean squared prediction error of the prediction formula using C 0h-C 12h were 0.1%, 7.6%, and 8.8%, respectively. In a hospital setting, a limited sampling strategy using C 0h-C 12h would be applicable to estimating the AUC 0-24 of tacrolimus once daily.

11 May 2022 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
SYSatoshi Yokoyama
Satoshi Yokoyama
JNJunichi Nakagawa
Junichi Nakagawa
NANaoya Aiuchi
Naoya Aiuchi
TSTatsuya Seito
Tatsuya Seito
TNTakenori Niioka
Takenori Niioka

4 October 2016 in Xenobiotica
Verified
Journal Article
Closed access
HKHideaki Kagaya
Hideaki Kagaya
TNTakenori Niioka
Takenori Niioka
MSMitsuru Saito
Mitsuru Saito
TITakamitsu Inoue
Takamitsu Inoue
KNKazuyuki Numakura
Kazuyuki Numakura
MMMasatomo Miura
Masatomo Miura
1. The objective of this study was to examine the association of UGT1A9, SLCO, and ABCC polymorphisms with mycophenolic acid (MPA) pharmacokinetics in ABO blood type (ABO) incompatible patients with severe renal dysfunction pre-transplantation. 2. In all patients, on day 14 after beginning mycophenolate mofetil (MMF) treatment (1 week before transplantation) and on day 28 after renal transplantation, samples were collected just prior to and 1, 2, 3, 4, 6, 9, and 12 h after oral MMF administration. 3. The median dose-adjusted AUC0–12 of MPA after renal transplantation was significantly lower than before transplantation (57.9 versus 76.5 μg h/mL, respectively, p = 0.002). 4. Although the enterohepatic circulation of MPA pre-transplantation was extremely high (57.6%), this level was significantly reduced after renal transplantation (34.6%). 5. In the multivariate analysis, pre-transplantation, patients with the SLCO1B3 334T allele (p = 0.003), higher alanine aminotransferase (p = 0.002), and lower body weight were independently predictive for a higher dose-adjusted AUC0–12 of MPA. 6. In patients with severe renal dysfunction pre-transplantation, MPA is excreted mainly to bile from the liver, and as a consequence, the SLCO1B3 334T > G polymorphism was found to be significantly associated with MPA exposure.